Corbus Pharmaceuticals (CRBP) vs Polaryx Therapeutics (PLYX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Corbus Pharmaceuticals is the larger company by market cap ($104.1 million vs $99.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRBP | PLYX |
|---|---|---|
| Share price | $5.38 | $2.00 |
| Market cap | $104.06M | $99.69M |
| 1-day change | +2.09% | 0.00% |
| YTD return | -33.91% | — |
| 1-year return | -65.73% | — |
| 5-year return | -82.42% | — |
| EPS (TTM) | $-6.11 | $-0.14 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $20.56 | $48.91 |
| 52-week low | $5.13 | $1.85 |
| Distance from 52-week high | -73.83% | -95.91% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +532.53% | +275.00% |
| Average volume | 756.54K | 76.41K |
| Shares outstanding | 19.34M | 49.85M |
| Employees | 36 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Corbus Pharmaceuticals
CRBP stock →Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity.
Health Care · Biotechnology: Pharmaceutical Preparations · 36 employees
About Polaryx Therapeutics
PLYX stock →Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
CRBP vs PLYX FAQ
Which is bigger, Corbus Pharmaceuticals or Polaryx Therapeutics?
Corbus Pharmaceuticals (CRBP) is larger, with a market capitalization of $104.06M compared with $99.69M for Polaryx Therapeutics (PLYX).
Are Corbus Pharmaceuticals and Polaryx Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.